Antitrust & Trade Reg.
Oct. 9, 2026
Takeda seeks arbitration of insurers' Dexilant antitrust claims
A San Francisco judge is weighing Takeda and TWi's bid to force health insurers into arbitration of claims that the drugmakers delayed generic competition for Dexilant.
A San Francisco judge is considering a bid by Takeda Pharmaceuticals and TWi Pharmaceuticals to force health insurers into arbitration of claims that the drugmakers delayed generic competition for the heartburn drug Dexilant.
Superior Court Judge Ethan P. Schulman said at a hearing Thursday he had circulated a tentative ruling partially granting the motion as to Humana Inc. The parties disputed whether arbitration provisions in agreements involving the insurers' affiliates bin...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In